Common Stock Reserved For Issuance

9 Months Ended

Sep. 30, 2021

Equity [Abstract]

Common Stock Reserved For Issuance

Note 10.  COMMON STOCK RESERVED FOR ISSUANCE

Common stock has been reserved for the following potential future issuances:

	As of September 30, 2021		As of December 31, 2020
Shares underlying outstanding stock options		1,147,457		832,868
Shares available for future stock option grants		403,430		267,275
Exchange of Vaccinex Products, LP units		-		1,147,259
Exchange of VX3 units		-		1,318,797
Total shares of common stock reserved		1,550,887		3,566,199

During the nine months ended September 30, 2021, exchange transactions were effected whereby all remaining limited partnership interests in VX3, and Vaccinex Products were exchanged for 1,318,797 and 1,147,259 shares of the Company’s common stock at par value of $0.0001 per share in accordance with the terms of the respective exchange agreements (see Note 15). During the nine months ended September 30, 2020, 18,565 units of Vaccinex Products were exchanged for shares of the Company’s common stock at par value of $0.0001 per share.